INHIBRX BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
INHIBRX BIOSCIENCES, INC. (INBX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $300.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-19
- INHIBRX BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-03-31 was $300.00K, a 96.39% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-06-30 was $34.20M.
- INHIBRX BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $42.50M, a 70.68% increase from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $24.90M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2025-03-31 | $300.00K 10-Q · filed 2025-05-14 | $300.00K derived: sum of 2 quarters · filed 2026-03-19 | $300.00K derived: sum of 3 quarters · filed 2026-03-19 | $34.50M derived: sum of 4 quarters · filed 2026-03-19 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $34.20M derived: sum of 3 quarters · filed 2026-03-19 | $42.50M 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $34.20M derived: sum of 2 quarters · filed 2025-11-14 | $42.50M 10-Q · filed 2025-11-14 | $48.40M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $34.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $42.50M 10-Q · filed 2025-08-13 | $48.40M derived: sum of 3 quarters · filed 2025-08-13 | $53.60M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $8.30M 10-Q · filed 2025-05-14 | $14.20M derived: sum of 2 quarters · filed 2025-05-14 | $19.40M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $5.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $11.10M derived: sum of 2 quarters · filed 2025-03-17 | $24.90M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $5.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $19.00M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $13.80M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |